Astrazeneca Ab

Justin Fairfield Bower

Jeffrey Philip Poyser

David Waterson

Jon James Gordon Winter

Bernard Christophe Barlaam

Paul Turner

Benedicte Delouvrie

Christine Marie Paul Lambert

Craig Steven Harris

Gilles Ouvry

Gary Fairley

Peter Wedderburn Kenny

Christine Lambert

Compounds of formula (I)Q-L-W&#x2014;C(&#x2550;X)&#x2014;Z&#x2014;Pwherein

Heterocyclic compounds as CCR2B antagonists

The invention concerns pyridine and pyrazine derivatives of Formula I or a pharmaceutically-acceptable salt thereof, wherein each of W, G, G, G, G, J, Ring A, n and Rhas any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.

Pyridine and pyrazine derivatives -083

A compound of formula (I)P&#x2014;W&#x2014;C(&#x2550;X)-L-Q&#x2003;&#x2003;(I)

Piperazine compounds useful as antagonists of C-C chemokines (Ccr2b and CcrS) for the treatment of inflammatory diseases

Compounds of formula (I) Q-L-W&#x2014;C(&#x2550;X)&#x2014;Z&#x2014;P wherein Q is an amine of the formula &#x2014;N(R)(R); L is an alkyl or heterocyclyl-alkyl linker; W is a 6- or 7-membered aliphatic ring comprising ring atoms Yand Ywhich are linked to groups L and C(X) respectively and Yand Yare independently selected from N and C; X is O, N, N&#x2014;CN or S; Z is NR; P is an optionally substituted monocyclic or bicyclic aryl or heteroaryl group; and pharmaceutically acceptable salts or solvates thereof, are useful in the treatment of C-C chemokine mediated conditions.

Heterocyclic compounds as ccr2b antagonists

Growing community of inventors

Cheshire, United Kingdom

Justin Fairfield Bower